Diabetes effects approximately 170 million people worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death as recorded on US death certificates.

The Global Diabetes drugs treatment market was valued of $15 billion in 2005. Oral anti-diabetics were the leading category of drugs - $8.19 billion - and showed a growth rate of 6.3% from the total global sales in 2004. The total sales for insulin products increased by 16.5% to total global sales of $6.83 billion in 2004.

Key Market for the Future...

Visiongain predicts that the retail market for diabetes medications will continue to show significant growth for what is an already large market. Actos from Takeda is the leading oral anti-diabetic product and appears set to retain this status. However, it is co-marketed with Eli Lilly which has new products to make available. Lantus from Sanofi-Aventis is the leading insulin product. But there are three new products available, including the world's first inhaled insulin product - Exubera from Pfizer.

Why you should buy this report:

Diabetes treatment is a leading therapeutic area and is about to become even more important.

The world's first inhaled insulin product has just been approved to the world's largest pharmaceutical company. This report will help you to assess just what impact that this is likely to have.

The market is dominated by a Japanese product - is this a sign of things to come from a previously struggling side of the industry?

Visiongain has taken the latest available financial statistics and forecast revenue figures for all the leading products.

The report contains analysis of the pipeline and potential blockbuster products of the next five years.